These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38820738)

  • 1. Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions.
    Lorefice L; Piras C; Sechi V; Barracciu MA; Cocco E; Fenu G
    J Neurol Sci; 2024 Jul; 462():123057. PubMed ID: 38820738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    Granella F; Tsantes E; Graziuso S; Bazzurri V; Crisi G; Curti E
    J Neurol; 2019 Dec; 266(12):3031-3037. PubMed ID: 31494713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
    Gavoille A; Rollot F; Casey R; Kerbrat A; Le Page E; Bigaut K; Mathey G; Michel L; Ciron J; Ruet A; Maillart E; Labauge P; Zephir H; Papeix C; Defer G; Lebrun-Frenay C; Moreau T; Berger E; Stankoff B; Clavelou P; Thouvenot E; Heinzlef O; Pelletier J; Al-Khedr A; Casez O; Bourre B; Cabre P; Wahab A; Magy L; Camdessanché JP; Doghri I; Moulin S; Ben-Nasr H; Labeyrie C; Hankiewicz K; Neau JP; Pottier C; Nifle C; Manchon E; Lapergue B; Wiertlewski S; De Sèze J; Vukusic S; Laplaud DA;
    JAMA Neurol; 2024 Aug; 81(8):814-823. PubMed ID: 38949816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Lim TRU; Kumaran SP; Suthiphosuwan S; Espiritu AI; Jones A; Lin AW; Oh J; Bharatha A
    Mult Scler; 2024 Apr; 30(4-5):505-515. PubMed ID: 38419027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    Lauerer M; McGinnis J; Bussas M; El Husseini M; Pongratz V; Engl C; Wuschek A; Berthele A; Riederer I; Kirschke JS; Zimmer C; Hemmer B; Mühlau M
    J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):37-43. PubMed ID: 37495267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Kunchok A; Lechner-Scott J; Granella F; Trojano M; Alroughani R; Sola P; Ferraro D; Lugaresi A; Onofrj M; Ozakbas S; Izquierdo G; Grammond P; Luis Sanchez-Menoyo J; Van Wijmeersch B; Boz C; Pucci E; McCombe P; Grand'Maison F; Spitaleri D; Vucic S; Hupperts R; Jokubaitis V; Sormani MP; Butzkueven H; Kalincik T;
    Mult Scler; 2021 Apr; 27(5):695-705. PubMed ID: 32639855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Barkhof F; Schoonheim MM; Strijbis EM; Vrenken H; Gallo A; Bisecco A; Ciccarelli O; Yiannakas M; Rovira A; Sastre-Garriga J; Palace J; Matthews L; Gass A; Eisele P; Lukas C; Bellenberg B; Margoni M; Preziosa P; Filippi M;
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):10-18. PubMed ID: 36171105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    Ruggieri S; Prosperini L; Petracca M; Logoteta A; Tinelli E; De Giglio L; Ciccarelli O; Gasperini C; Pozzilli C
    J Neurol; 2023 Oct; 270(10):4995-5003. PubMed ID: 37386292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability.
    Bussas M; El Husseini M; Harabacz L; Pineker V; Grahl S; Pongratz V; Berthele A; Riederer I; Zimmer C; Hemmer B; Kirschke JS; Mühlau M
    Neuroimage Clin; 2022; 34():103006. PubMed ID: 35468568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Zecca C; Disanto G; Sormani MP; Riccitelli GC; Cianfoni A; Del Grande F; Pravatà E; Gobbi C
    Mult Scler; 2016 May; 22(6):782-91. PubMed ID: 26459149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.
    Brownlee WJ; Altmann DR; Prados F; Miszkiel KA; Eshaghi A; Gandini Wheeler-Kingshott CAM; Barkhof F; Ciccarelli O
    Brain; 2019 Aug; 142(8):2276-2287. PubMed ID: 31342055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Hao Q; Kanda M; Tani Y
    BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study.
    Dallera G; Affinito G; Caliendo D; Petracca M; Carotenuto A; Triassi M; Brescia Morra V; Palladino R; Moccia M
    Mult Scler Relat Disord; 2023 Jan; 69():104423. PubMed ID: 36436395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.
    Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH
    Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
    Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
    Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Dekker I; Sombekke MH; Witte BI; Geurts JJ; Barkhof F; Uitdehaag BM; Killestein J; Wattjes MP
    Mult Scler; 2018 Apr; 24(4):481-490. PubMed ID: 29106327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.